vs
Side-by-side financial comparison of AMERISAFE INC (AMSF) and Syndax Pharmaceuticals Inc (SNDX). Click either name above to swap in a different company.
AMERISAFE INC is the larger business by last-quarter revenue ($80.1M vs $68.5M, roughly 1.2× Syndax Pharmaceuticals Inc). AMERISAFE INC runs the higher net margin — 10.2% vs -99.3%, a 109.5% gap on every dollar of revenue. On growth, Syndax Pharmaceuticals Inc posted the faster year-over-year revenue change (791.7% vs 10.3%).
AMERISAFE Inc. is a specialty insurance provider that focuses exclusively on workers' compensation coverage for small and mid-sized businesses in high-hazard industries including construction, logging, trucking, and manufacturing. It operates across 49 U.S. states, offering tailored insurance policies paired with targeted risk management support for clients.
Syndax Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies for patients with hard-to-treat cancers. Its pipeline includes targeted and immunotherapy candidates addressing unmet medical needs, primarily serving global oncology healthcare stakeholders and patient populations.
AMSF vs SNDX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $80.1M | $68.5M |
| Net Profit | $8.1M | $-68.0M |
| Gross Margin | — | — |
| Operating Margin | — | -91.3% |
| Net Margin | 10.2% | -99.3% |
| Revenue YoY | 10.3% | 791.7% |
| Net Profit YoY | -9.0% | 27.8% |
| EPS (diluted) | $0.43 | $-0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $80.1M | — | ||
| Q4 25 | $81.6M | $68.5M | ||
| Q3 25 | $82.0M | $45.9M | ||
| Q2 25 | $81.1M | $38.0M | ||
| Q1 25 | $72.6M | $20.0M | ||
| Q4 24 | $74.0M | — | ||
| Q3 24 | $78.7M | $12.5M | ||
| Q2 24 | $75.8M | — |
| Q1 26 | $8.1M | — | ||
| Q4 25 | $10.4M | $-68.0M | ||
| Q3 25 | $13.8M | $-60.7M | ||
| Q2 25 | $14.0M | $-71.8M | ||
| Q1 25 | $8.9M | $-84.8M | ||
| Q4 24 | $13.2M | — | ||
| Q3 24 | $14.3M | $-84.1M | ||
| Q2 24 | $11.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | -91.3% | ||
| Q3 25 | 21.3% | -125.2% | ||
| Q2 25 | 21.5% | -182.7% | ||
| Q1 25 | 15.5% | -417.9% | ||
| Q4 24 | 22.7% | — | ||
| Q3 24 | 22.6% | -716.6% | ||
| Q2 24 | 18.1% | — |
| Q1 26 | 10.2% | — | ||
| Q4 25 | 12.8% | -99.3% | ||
| Q3 25 | 16.9% | -132.4% | ||
| Q2 25 | 17.2% | -189.3% | ||
| Q1 25 | 12.3% | -423.3% | ||
| Q4 24 | 17.8% | — | ||
| Q3 24 | 18.2% | -673.0% | ||
| Q2 24 | 14.5% | — |
| Q1 26 | $0.43 | — | ||
| Q4 25 | $0.55 | $-0.78 | ||
| Q3 25 | $0.72 | $-0.70 | ||
| Q2 25 | $0.73 | $-0.83 | ||
| Q1 25 | $0.47 | $-0.98 | ||
| Q4 24 | $0.69 | — | ||
| Q3 24 | $0.75 | $-0.98 | ||
| Q2 24 | $0.57 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.2M | $394.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $246.6M | $64.6M |
| Total Assets | — | $529.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $34.2M | — | ||
| Q4 25 | $61.9M | $394.1M | ||
| Q3 25 | $54.7M | $436.0M | ||
| Q2 25 | $48.5M | $455.2M | ||
| Q1 25 | $44.8M | $512.2M | ||
| Q4 24 | $44.1M | — | ||
| Q3 24 | $63.7M | $389.6M | ||
| Q2 24 | $30.6M | — |
| Q1 26 | $246.6M | — | ||
| Q4 25 | $251.6M | $64.6M | ||
| Q3 25 | $274.8M | $115.4M | ||
| Q2 25 | $265.6M | $157.4M | ||
| Q1 25 | $260.8M | $215.1M | ||
| Q4 24 | $257.3M | — | ||
| Q3 24 | $314.4M | $366.4M | ||
| Q2 24 | $301.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $529.7M | ||
| Q3 25 | $1.2B | $551.8M | ||
| Q2 25 | $1.2B | $596.1M | ||
| Q1 25 | $1.2B | $640.7M | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.3B | $425.8M | ||
| Q2 24 | $1.2B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-69.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $11.1M | $-69.5M | ||
| Q3 25 | $10.7M | $-70.5M | ||
| Q2 25 | $-8.4M | $-87.8M | ||
| Q1 25 | $-1.8M | $-95.2M | ||
| Q4 24 | $24.2M | — | ||
| Q3 24 | $8.4M | $-62.3M | ||
| Q2 24 | $-2.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | $8.9M | — | ||
| Q3 25 | $9.8M | — | ||
| Q2 25 | $-9.5M | — | ||
| Q1 25 | $-1.8M | — | ||
| Q4 24 | $23.4M | — | ||
| Q3 24 | $8.4M | — | ||
| Q2 24 | $-2.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | 10.9% | — | ||
| Q3 25 | 11.9% | — | ||
| Q2 25 | -11.7% | — | ||
| Q1 25 | -2.5% | — | ||
| Q4 24 | 31.5% | — | ||
| Q3 24 | 10.7% | — | ||
| Q2 24 | -3.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.06× | — | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | -0.61× | — | ||
| Q1 25 | -0.20× | — | ||
| Q4 24 | 1.83× | — | ||
| Q3 24 | 0.59× | — | ||
| Q2 24 | -0.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
